Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
Better serving global partners and advancing healthcare innovation
Subscribe To Our Newsletter & Stay Updated
